ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Genentech to pay Immunocore $100 million to codevelop bispecific solid tumor therapy

by Ryan Cross
November 22, 2018 | APPEARED IN VOLUME 96, ISSUE 47

Genentech is paying $100 million in up-front and near-term payments to Immunocore to codevelop its experimental cancer therapy IMC-C103C. The drug candidate will be tested in clinical trials next year and targets a cancer antigen called melanoma-associated antigen A4 (MAGE-A4), which is found in multiple types of solid tumors.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment